title: [Clinical feature and prognosis analysis of elderly patients with polythemia vera].
abstract: OBJECTIVE
  To analyze the clinical features of elderly patients with polythemia vera (PV).
  
  
  METHODS
  Statistical analyses were performed for the clinical features of 68 PV patients of age≥60 years and 72 PV patients of age<60 years from January 2009 to December 2013 in our hospital.
  
  
  RESULTS
  Compared with younger patients, elderly patients with PV had higher incidences of thrombosis (54.4% (37/68) vs 30.6% (22/72), P=0.004), more risk factors of cardio-cerebrovascular (63.2% (43/68) vs 36.1% (26/72), P=0.001), higher white blood cell counts ((13.9±3.8)×10(9)/L vs (7.8±2.2)×10(9)/L, P=0.000) and higher JAK2 V617F allele burden (62% (30%-81%) vs 41% (26%-63%), P=0.035). There was higher incidences of vascular complications in elderly patients with PV (54.4% (37/68) vs 30.6% (22/72), P=0.004). Myelofibrosis transformation occurred with higher frequency in elderly patients with PV (11.8% (8/68) vs 2.8% (2/72), P=0.039). And there was no significant difference in the frequency of leukemia transformation between elderly patients and younger patients (4.4% (3/68) vs 0 (0/72), P=0.112). There was higher mortality rate in elderly patients with PV (14.7% (10/86) vs 4.2% (3/72), P=0.032).
  
  
  CONCLUSIONS
  There are more risk factors in elderly patients with PV. The elderly patients with PV has high risk to complicat with thrombosis and transformated to myelofibrosis and leukemia. Prevention or delay of these complications is currently the goal of treatment, so that it could reduce the mortality rate and disease progression.
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Xiao
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China; Email: zmfzmf@hotmail.com.
authors.forename: Mingfeng
authors.initials: M
authors.lastname: Zhao
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Juanxia
authors.initials: J
authors.lastname: Meng
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Mu
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Hairong
authors.initials: H
authors.lastname: Lü
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Pengjiang
authors.initials: P
authors.lastname: Liu
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Deng
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Li
authors.initials: L
authors.lastname: Geng
authors.affiliation: Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Yuming
authors.initials: Y
authors.lastname: Li
mesh_terms: D000368:Aged; D000483:Alleles; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D006801:Humans; D053614:Janus Kinase 2; D007938:Leukemia; D011087:Polycythemia Vera; D055728:Primary Myelofibrosis; D011379:Prognosis; D013927:Thrombosis
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2